🇺🇸 FDA
Pipeline program

ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets

APHP230831

Phase 2 small_molecule active

Quick answer

ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets for Folliculitis decalvans is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Folliculitis decalvans
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials